Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.44 |
| ▸ | NOS1 | P29475 | 7/20 | 0.44 |
| ▸ | NOS2 | P35228 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | FHIT | P49789 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833973 | 0.89 | NOS3 (0.42) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL7083838 | 0.85 | NOS3 (0.51) | NOS3NOS1NOS2RXRARXRB | |
| SCHEMBL5834000 | 0.84 | NOS3 (0.45) | NOS3NOS1NOS2RXRARXRB | |
| SCHEMBL7956318 | 0.84 | FHIT (0.37) | PPARDPPARGKDM4EFHITPPARA | |
| SCHEMBL5833803 | 0.82 | NOS3 (0.67) | NOS3NOS1NOS2KDM4E | |
| SCHEMBL6153077 | 0.80 | NOS3 (0.46) | NOS3NOS1NOS2PPARDKDM4E | |
| SCHEMBL5833910 | 0.79 | NOS3 (0.46) | NOS3NOS1NOS2PPARDPPARG | |
| SCHEMBL5833170 | 0.78 | NOS3 (0.35) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL7086013 | 0.77 | NOS3 (0.49) | NOS3NOS1NOS2KDM4E | |
| SCHEMBL5833902 | 0.74 | NOS3 (0.41) | NOS3NOS1NOS2PPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1155000-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6372768-B2 | NERVOUS SYSTEM DISORDERS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1155000-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | disclosed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| WO-2000050400-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | CBR1, CBR3, NOS2 | NOS3 4/4885NOS1 5/4885NOS2 3/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.